TOP > 外国特許検索 > THERAPEUTIC AGENT FOR SCLERODERMA

THERAPEUTIC AGENT FOR SCLERODERMA

外国特許コード F150008233
掲載日 2015年3月26日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2014JP057936
国際公開番号 WO 2014142356
国際出願日 平成26年3月14日(2014.3.14)
国際公開日 平成26年9月18日(2014.9.18)
優先権データ
  • 特願2013-054090 (2013.3.15) JP
発明の名称 (英語) THERAPEUTIC AGENT FOR SCLERODERMA
発明の概要(英語) The purpose of the present invention is to provide a novel therapeutic agent for scleroderma, and specifically relates to a therapeutic agent for scleroderma, containing as an active ingredient a conjugate in which cytotoxin or a cytotoxic agent and an antibody that binds to folate receptor β (FRβ) are conjugated.
従来技術、競合技術の概要(英語) BACKGROUND ART
Scleroderma is, one of collagen, fibrosis and the various portions of the body and the skin lesion is developing a chronic disease of unknown origin. As the pathology of scleroderma, activation of fibroblasts (such as collagen accumulation of the extracellular matrix), and vascular disorders and immune disorders (autoantibodies). As one of the pathogenesis of scleroderma, early infiltration of macrophages by the secretion from macrophages infiltrated the increase TGF-β has attracted attention. At an early stage of fibrosis in the activated macrophage is a cell infiltration of the first, TGF-β, CTGF, secreting factors such as PDGF scleroderma fibrosis is presumed to play an important role in the course of which the (non-patent document 1 and 2). In the current state of treatment of scleroderma, early patient for adrenal cortex steroid drug is generally used, also for the immunosuppressant in the pulmonary condition generally used. In addition, methods of treatment of interleukin 2 during the study, an inhibition of cytokines such as TGF-β are directed. For example, anti-TGF-β antibody treatment showed significant therapeutic effect have been reported (non-patent document 3). However, in the related art, the progression of scleroderma is completely curative treatment which has not been established. On the other hand, the inventors of the present invention, the folate receptor β (FR β) inflammation of the synovium of rheumatoid arthritis at the time of tissue macrophages is highly expressed in macrophages, fibroblasts that removal of the positive macrophages FR β activation of the reported that inhibit angiogenesis (non-patent document 4 and 5). In addition, the inventors of the present invention, anti-FR β antibody heavy chain variable region (VH) and P. aeruginosa toxin (PE) are linked with a fusion protein, anti-FR β antibody light chain variable region (VL) of recombinant immunotoxins composed of anti-FR β as an active ingredient interstitial (patent document 1) discloses a therapeutic agent. However, non-patent document 4 and 5 as well as any of the patent document 1, the anti-recombinant immunotoxins FR β can be used to treat scleroderma is not disclosed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • 発明者(英語)
  • MATSUYAMA, Takami
  • LI, Hua
  • NAGAI, Taku
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close